CRL

Business profile & competitive position

Charles River Laboratories International, Inc. operates in the Healthcare sector, specifically the Medical – Diagnostics & Research industry. The company is a full-service, non-clinical global drug development partner, providing research model technologies, discovery and safety assessment services (both GLP and non-GLP), and manufacturing support products and services. Its operations are organized into three reportable segments. In 2025, total revenue was $4.0 billion, with Research Models and Services (RMS) contributing 21.1%, Discovery and Safety Assessment (DSA) contributing 59.8%, and Manufacturing Solutions contributing 19.1%. The company runs more than 120 sites across more than 20 countries.

The revenue split makes DSA the dominant driver, while RMS and Manufacturing provide material but smaller contributions. The broad geographic footprint can support scale, but the margin profile does not currently point to a strong pricing or cost moat. Net margin is negative 6.0% and return on equity is negative 7.7%. When a services business posts negative returns on equity, the financials are not confirming durable excess profitability or tight customer captivity. Instead, the numbers suggest a company whose competitive position is under pressure and where execution, rather than structural dominance, is the main variable.

Financial posture

CRL carries a market capitalization of $14.1 billion, yet the stock trades at a negative P/E of -60.5. That negative multiple reflects the firm’s current loss position: net margin is -6.0% and ROE is -7.7%. Investors are therefore valuing the company on a hoped-for recovery in profitability rather than on trailing earnings. At the current snapshot, the share price is $292.84, while the 50-day exponential moving average sits at $267.23, meaning price is above that short-term trend line. The RSI is 59.9, a level that is neither clearly oversold nor overbought.

A beta of 1.41 indicates the stock has historically moved substantially more than the broader market. That higher volatility fits a turnaround story where earnings are negative but the market is pricing in restructuring outcomes and future margin expansion. The combination of negative margins, negative ROE, and a forward-looking valuation leaves the financial posture dependent on management’s ability to convert strategic plans into actual earnings. The figures themselves do not confirm that conversion has already happened.

Strategic priorities & outlook

Charles River’s most recent SEC 10-K filing outlines a strategy built on footprint rationalization, organizational integration, and biologics expansion. Over the next two years, the company expects to close or consolidate approximately 12 additional sites, mainly within DSA and RMS. That move is aimed at simplifying operations and taking cost out of the network. At the same time, Discovery Services and Safety Assessment are being merged into one overarching DSA organization, with a combined sales force and leadership structure. The stated goal is to act as the scientific partner of choice by offering a comprehensive, integrated portfolio that can accelerate biomedical research and therapeutic innovation.

On the growth side, the company intends to keep expanding its Biologics Testing Solutions service offerings and facilities in the U.S. and Europe. It is also addressing supply inputs directly: in January 2026, Charles River acquired certain assets of K.F. (Cambodia) Ltd., a provider of non-human primates, to support DSA supply operations and RMS third-party sales. These priorities are consistent with a business trying to recover profitability by lowering its cost base, tightening its go-to-market, and securing supply-chain access for animal-reliant research services.

Macro & geopolitical exposure

As a Healthcare/Medical – Diagnostics & Research company focused on non-clinical drug development, Charles River is exposed to the cyclicality of pharmaceutical and biotechnology R&D spending, as well as to the funding health of its client base. Demand for discovery, safety assessment, and manufacturing support services typically tracks biopharma investment budgets and capital-market access for smaller biotech customers.

The business also carries regulatory and trade exposure. Safety assessment work is governed by GLP and other FDA/EMA standards, so changes in regulatory requirements or enforcement intensity can affect study protocols and costs. Because the company operates more than 120 sites in over 20 countries, currency translation is another real factor in reported results. Trade policy can matter too: research models, biological materials, and non-human primate supply chains can be subject to import tariffs, export controls, or shipment restrictions. Animal-use regulations and activist-driven restrictions on primate research represent additional headline risks for the RMS and DSA segments. Finally, global supply-chain conditions for animal husbandry, laboratory consumables, and specialized biologics inputs can influence margins.

Recent developments

On September 25, 2026, MarketBeat reported that Charles River is targeting 5%-7% growth and $300 million in savings under a 2030 plan. That same framework was the focus of the company’s 2026 Investor Day on September 24, 2026, where BusinessWire highlighted a “refreshed strategic vision to drive profitable growth and long-term value creation,” and Seeking Alpha published the analyst/investor day transcript. DefenseWorld.net also published a financial comparison of Charles River Laboratories against Adaptive Biotechnologies on September 24, 2026.

Taken together, the news flow centers on a multi-year plan aimed at growth and cost savings. The $300 million savings target and the 5%-7% growth objective are now public benchmarks against which investors will likely judge management. The Investor Day materials provide the context for how the company intends to reach those targets, including the footprint optimization and DSA integration already described in its 10-K.

Earnings behavior & post-earnings drift

Charles River has beaten analyst EPS estimates in all of the last eight reported quarters, for a 100% beat rate over that span. The average earnings surprise across those eight quarters is 9.3%, and the average five-day price move after earnings is +1.24%, classified as an “up” drift. That pattern suggests the company has consistently exceeded the official consensus, though the market’s reaction has varied.

The most recent four quarters illustrate that divergence. On August 5, 2026, CRL reported EPS of $3.02 against an estimate of $2.74, a 10.2% surprise; the stock rose 1.84% the next day and 9.07% over the following five sessions. On May 7, 2026, it reported EPS of $2.06 versus $1.96, a 5.1% beat, yet the stock fell 2.23% the next day and 12.42% over the next five sessions. The February 18, 2026 quarter brought EPS of $2.39 versus $2.33, a 2.6% surprise, with the stock up 3.95% the next day and 6.05% over five days. The November 5, 2025 quarter showed EPS of $2.43 versus $2.32, a 4.7% beat, driving a 1.9% next-day gain and a 2.27% five-day gain.

So while the average post-earnings drift is positive, the dispersion is wide. A beat does not guarantee a rally, as the May 2026 reaction demonstrated. Looking ahead, the next scheduled earnings release is November 4, 2026, before the open, with a consensus EPS estimate of $2.96. Traders watching the event should weigh the 100% historical beat rate and 9.3% average surprise against the uneven price follow-through, since the market’s real expectation may already embed more than the published estimate.

For a deeper dive into CRL, including the full range of analyst ratings, price targets, and institutional sentiment, review the full institutional verdict on the ticker page.